Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva

MT Newswires Live03-13

Armata Pharmaceuticals (ARMP) said late Wednesday it has entered into a secured credit agreement with Innoviva Strategic Opportunities, a subsidiary of its largest shareholder, Innoviva (INVA), for gross proceeds of $10 million.

The term loan has an interest rate of 14% per annum and a maturity date of March 12, 2026.

The company said it plans to use the proceeds to advance its lead therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infectious caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.

The companies also entered into amendments to three previous credit and security agreements to extend their maturity dates to March 12, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2519393002?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-13 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519393002","market":"us","top_or_hot":-1,"title":"Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva","media":"MT Newswires Live","content":"<html><body><p> Armata Pharmaceuticals (ARMP) said late Wednesday it has entered into a secured credit agreement with Innoviva Strategic Opportunities, a subsidiary of its largest shareholder, Innoviva (INVA), for gross proceeds of $10 million.</p><p>The term loan has an interest rate of 14% per annum and a maturity date of March 12, 2026.</p><p>The company said it plans to use the proceeds to advance its lead therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infectious caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.</p><p>The companies also entered into amendments to three previous credit and security agreements to extend their maturity dates to March 12, 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArmata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-13 16:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Armata Pharmaceuticals (ARMP) said late Wednesday it has entered into a secured credit agreement with Innoviva Strategic Opportunities, a subsidiary of its largest shareholder, Innoviva (INVA), for gross proceeds of $10 million.</p><p>The term loan has an interest rate of 14% per annum and a maturity date of March 12, 2026.</p><p>The company said it plans to use the proceeds to advance its lead therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infectious caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.</p><p>The companies also entered into amendments to three previous credit and security agreements to extend their maturity dates to March 12, 2026.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2519393002","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519393002","pubTimestamp":1741854977,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Armata Pharmaceuticals  said late Wednesday it has entered into a secured credit agreement with Innoviva Strategic Opportunities, a subsidiary of its largest shareholder, Innoviva , for gross proceeds of $10 million.The term loan has an interest rate of 14% per annum and a maturity date of March 12, 2026.The company said it plans to use the proceeds to advance its lead therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infectious caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.The companies also entered into amendments to three previous credit and security agreements to extend their maturity dates to March 12, 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INVA":"Innoviva, Inc.","ARMP":"Armata Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Armata Pharmaceuticals与Innoviva签订1000万美元担保信贷协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARMP":0.9,"INVA":1},"content_text":"Armata Pharmaceuticals (ARMP) said late Wednesday it has entered into a secured credit agreement with Innoviva Strategic Opportunities, a subsidiary of its largest shareholder, Innoviva (INVA), for gross proceeds of $10 million.The term loan has an interest rate of 14% per annum and a maturity date of March 12, 2026.The company said it plans to use the proceeds to advance its lead therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infectious caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.The companies also entered into amendments to three previous credit and security agreements to extend their maturity dates to March 12, 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2519393002"}